Showing results (61-70 of 67) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Journal for Immunotherapy of Cancer|April 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trialMatthew S Block, Garth D Nelson, Jun Chen, et al.Frontiers in Immunology|November 29, 2023
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responsesKatherine E R Smith, Kah-Whye Peng, Jose S Pulido, et al.Nature Communications|February 16, 2024
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trialTina J Hieken, Garth D Nelson, Thomas J Flotte, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2024
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic MalignanciesEleftheria Kalogera, Wendy K Nevala, Heidi D Finnes, et al.Nature Communications|March 14, 2025
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trialJacob J Orme, Henan Zhang, Prashanth Lingamaneni, et al.Nature Medicine|February 7, 2025
Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trialEthan Basch, Deborah Schrag, Jennifer Jansen, et al.JAMA|June 6, 2022
Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical TrialEthan Basch, Deborah Schrag, Sydney Henson, et al.Pageof 7